scholarly journals SAT0636-HPR PATIENT EXPERIENCE WITH THE PRESCRIPTION, INFORMATION AND USE OF METHOTREXATE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1277.3-1278
Author(s):  
T. Oton ◽  
L. Carmona ◽  
J. L. Andréu Sánchez
Keyword(s):  
Side Effects ◽  
Focus Groups ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Physical Symptoms ◽  
Number Of Factors ◽  
Graphic Information ◽  
Main Barrier ◽  
And Training

Background:Methotrexate (MTX) is currently a mainstream drug in the treatment of rheumatic diseases. However, the response to MTX is not universal and may be conditioned by a number of factors, among which adherence could be crucial.Objectives:The aim of this study is to explore adherence to MTX in patients with rheumatic diseases, facilitators and perceived when taking and maintaining the prescription.Methods:A qualitative study of content analysis was performed. Focus groups with patients taking either oral or subcutaneous MTX (being the main or coadjuvant treatment) for any rheumatic disease was performed. The groups were moderated by a rheumatologist that was unknown for the patients. The speech was recorded and transcribed. Subsequently, an inductive coding was performed with the help of Atlas.ti and main themes and sub-themes were extracted, with examples of verbatim anonymized speech.Results:Three focus groups were conducted, with a total of 12 participants, of whom eight were women, seven had rheumatoid arthritis, three had psoriatic arthritis, one had spondyloarthritis, and one had systemic lupus erythematosus. All patients reported an adequate adherence to treatment. The barriers identified were: information in the leaflet, technical language in the consults, difficult access to doctor´s appointment, social environment, side effects and the subcutaneous device. As facilitators, the following aspects were discussed: good predisposition of the physician, reliable graphic information, role of associations and partners support.The unmet needs detected were: problems with travelling, protocols for eventualities, absence of a plan of care, neglection of “non-physical” symptoms, disinformation on side effects and training in complementary aspects.Conclusion:Getting reliable information was the main barrier identified. The environment and side effects may also negatively impact on adherence. Shared decision making is a goal to be achieved in the future in these patients.Disclosure of Interests:Teresa Oton Consultant of: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gebro Pharma, SA (All trhough institution), Loreto Carmona Grant/research support from: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gebro Pharma, SA (All trhough institution), José Luis Andréu Sánchez: None declared

scholarly journals EXPERİMENTAL-PSYCHOLOGİCAL RESEARCH AS A MAİN FACTOR İN SELF- ACTUALİZATİON AND PROFESSİON SELECTİON OF ADOLESCENTS

2019 ◽  
Vol 8 (7) ◽  
Author(s):  
Sevinj Orujova
Keyword(s):  
Self Esteem ◽  
Psychological Research ◽  
Self Assessment ◽  
Training Costs ◽  
Number Of Factors ◽  
Self Actualization ◽  
And Training ◽  
Selection Of ◽  
Main Factor

The article is devoted to the study of the role of self-actualization and profession motives in the profession selection in adolescents. Research has shown that increasing the level of self-actualization in adolescents depends on a number of factors, including the self-esteem of adolescents, changing their attitudes towards their potential and the nature of the formative work carried out with them. However, research has shown that there is a correlative dependency, and this dependence is positive, between adolescents' profession selection and self-assessment, self-actualization, and training costs.

scholarly journals Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

2020 ◽  
Vol 21 (19) ◽  
pp. 7100
Author(s):  
Carlos Rafael-Vidal ◽  
Nair Pérez ◽  
Irene Altabás ◽  
Samuel Garcia ◽  
Jose M. Pego-Reigosa
Keyword(s):  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Therapeutic Option ◽  
Premature Mortality ◽  
Interleukin 17 ◽  
Multiple Organs ◽  
Systemic Rheumatic Diseases ◽  
Bacteria And Fungi ◽  
Potential Use

Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option.

scholarly journals Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases

2011 ◽  
Vol 11 ◽  
pp. 1932-1947 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Rodolfo Gómez ◽  
Veronica López ◽  
Francisca Lago ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Adipose Tissue ◽  
Rheumatic Diseases ◽  
White Adipose Tissue ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Novel Concept

The cloning of leptin in 1994 by Zhang et al. introduced a novel concept about white adipose tissue (WAT) as a very dynamic organ that releases a plethora of immune and inflammatory mediators, such as adipokines and cytokines, which are involved in multiple diseases. Actually, adipokines exert potent modulatory actions on target tissues involved in rheumatic diseases including cartilage, synovial, bone and immune cells. The goal of this paper is to elucidate the recent findings concerning the involvement of adipokines in rheumatic diseases, such as rheumatoid arthritis (RA), osteoarthritis (OA), and systemic lupus erythematosus (SLE).

scholarly journals Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Rodolfo Gómez ◽  
Verónica López ◽  
Jesús Pino ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cardiovascular Complications ◽  
Risk Of Mortality ◽  
Increased Risk ◽  
Pathologic Alteration ◽  
Holistic Vision

Patients with rheumatic diseases have an increased risk of mortality by cardiovascular events. In fact, several rheumatic diseases such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis are associated with a higher prevalence of cardiovascular diseases (CVDs). Although traditional cardiovascular risk factors have been involved in the pathogenesis of cardiovascular diseases in rheumatic patients, these alterations do not completely explain the enhanced cardiovascular risk in this population. Obesity and its pathologic alteration of fat mass and dysfunction, due to an altered pattern of secretion of proinflammatory adipokines, could be one of the links between cardiovascular and rheumatic diseases. Indeed, the incidence of CVDs is augmented in obese individuals with rheumatic disorders. Thus, in this paper we explore in detail the relationships among adipokines, rheumatic diseases, and cardiovascular complications by giving to the reader a holistic vision and several suggestions for future perspectives and potential clinical implications.

scholarly journals Diagnostic and prognostic role of renal histopathology in rheumatic diseases

Reumatismo ◽  
2018 ◽  
pp. 165-177
Author(s):  
F. Saccon ◽  
M. Gatto ◽  
M. Larosa ◽  
F. Ometto ◽  
M. Felicetti ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Renal Involvement ◽  
Direct Result ◽  
Prognostic Role ◽  
Disease Treatment ◽  
Therapeutic Decisions ◽  
Systemic Rheumatic Diseases ◽  
Per Se

The objective was to evaluate renal involvement in several rheumatic diseases (i.e. rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis, systemic vasculitides). The method chosen was to define histopathological profiles reported in renal biopsies performed on patients with renal involvement due to different rheumatic diseases. Renal involvement observed in patients with rheumatic disease can be the direct result of the disease per se and/or a complication of drugs used in the disease treatment. The clinical-pathological correlations derived from the study of renal tissues can be useful for differential diagnosis, prognosis assessment and therapeutic decisions. Renal biopsy should be considered as an important tool for the management of nephropathies in patients with systemic rheumatic diseases.

Transitioning to Employment with a Rheumatic Disease: The Role of Independence, Overprotection, and Social Support

2014 ◽  
Vol 41 (12) ◽  
pp. 2386-2394 ◽  
Author(s):  
Arif Jetha ◽  
Elizabeth Badley ◽  
Dorcas Beaton ◽  
Paul R. Fortin ◽  
Natalie J. Shiff ◽  
...  
Keyword(s):  
Social Support ◽  
Young Adults ◽  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Multivariable Analysis ◽  
Online Questionnaire ◽  
Job Accommodation ◽  
Employment Participation

Objective.To examine perceived independence, overprotection, and support, and their association with the employment participation of young adults with rheumatic disease.Methods.One hundred and forty-three young adults, ages 18 to 30 years, with systemic lupus erythematosus (54.5%) and juvenile arthritis (45.5%) completed a 30-min online questionnaire of their work and education experiences. Information collected was demographic, health (e.g., pain, fatigue, disease activity), work context (e.g., career satisfaction, helpfulness of job accommodation/benefits, and workplace activity limitations), and psychosocial (e.g., independence, social support, and overprotection). Log-Poisson regression analysis examined factors associated with employment status.Results.Over half of respondents were employed (59%) and 26% were enrolled in school. Respondents reported moderate to high perceptions of independence and social support. However, 27% reported that “quite a bit” to “a great deal” of overprotection characterized their relationships with those closest to them. At the bivariate level, employed participants and those indicating greater perceived independence reported greater social support and less overprotection. Multivariable analysis revealed that being employed was associated with older age, more job accommodations/benefits perceived as being helpful, and greater perceived independence.Conclusion.This is one of the first studies examining the employment of young adults with rheumatic diseases. Findings highlight the importance of psychosocial perceptions such as independence and overprotection, in addition to support related to working. Additional research is needed to better understand the role of those close to young adults with rheumatic diseases in supporting independence and encouraging employment.

scholarly journals IL-33 in Rheumatic Diseases

2021 ◽  
Vol 8 ◽  
Author(s):  
Yuanji Dong ◽  
Jixin Zhong ◽  
Lingli Dong
Keyword(s):  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Nk Cell ◽  
Killer Cell ◽  
Inflammatory Cells ◽  
Protective Role ◽  
Cell Group ◽  
Cancer Tissue ◽  
Interleukin 33

Interleukin-33 (IL-33) is a nuclear factor mainly expressed in barrier epithelium, endothelial cells, and fibroblast reticular cells. Some inflammatory cells also express IL-33 under certain conditions. The important role of IL-33 in allergic reactions, helminth infection, cancer, tissue fibrosis, chronic inflammation, organ transplantation, and rheumatic immune diseases has been extensively studied in recent years. IL-33 primarily activates various circulating and tissue-resident immune cells, including mast cell, group 2 innate lymphoid cell (ILC2), regulatory T cell (Treg), T helper 2 cell (Th2), natural killer cell (NK cell), and macrophage. Therefore, IL-33 plays an immunomodulatory role and shows pleiotropic activity in different immune microenvironments. The IL-33/serum stimulation-2 (ST2) axis has been shown to have a detrimental effect on rheumatoid arthritis, systemic lupus erythematosus, and other rheumatic diseases. Interestingly, IL-33 also plays a protective role in the repair of barrier epithelium and the activation of Tregs. Therefore, the role of IL-33/ST2 depends on the underlying pathological conditions in rheumatic diseases. This review focuses on the dual role of the IL-33/ST2 axis in rheumatic diseases.

scholarly journals The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 462 ◽  
Author(s):  
Ilan Bank
Keyword(s):  
T Cells ◽  
T Cell ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cell Biology ◽  
Γδ T Cells ◽  
Immune Functions ◽  
Autoimmune Rheumatic Diseases ◽  
New Therapeutic Approaches

Autoimmune rheumatic diseases (ARDs), affecting ~1–1.5% of all humans, are associated with considerable life long morbidity and early mortality. Early studies in the 1990s showed numerical changes of the recently discovered γδ T cells in the peripheral blood and in affected tissues of patients with a variety of ARDs, kindling interest in their role in the immuno-pathogenesis of these chronic inflammatory conditions. Indeed, later studies applied rapid developments in the understanding of γδ T cell biology, including antigens recognized by γδ T cells, their developmental programs, states of activation, and cytokine production profiles, to analyze their contribution to the pathological immune response in these disorders. Here we review the published studies addressing the role of γδ T in the major autoimmune rheumatic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, systemic lupus erythematosus and scleroderma, and animal models thereof. Due to their unique properties spanning adaptive and innate immune functions, the ever deeper understanding of this unique T cell population is shedding new light on the pathogenesis of, while potentially enabling new therapeutic approaches to, these diseases.

scholarly journals Inflammation and Coronary Microvascular Dysfunction in Autoimmune Rheumatic Diseases

2019 ◽  
Vol 20 (22) ◽  
pp. 5563 ◽  
Author(s):  
Elisabetta Zanatta ◽  
Claudia Colombo ◽  
Gianpiero D’Amico ◽  
Thomas d’Humières ◽  
Carlo Dal Lin ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Systemic Vasculitis ◽  
Microvascular Dysfunction ◽  
Current Evidence ◽  
Coronary Microvascular Dysfunction ◽  
Channel Blockers ◽  
Autoimmune Rheumatic Diseases ◽  
Cardiovascular Morbidity And Mortality

Autoimmune rheumatic diseases (ARDs) form a heterogeneous group of disorders that include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIMs), and systemic vasculitis. Coronary microvascular dysfunction (CMD) is quite common in patients with ARDs and is linked to increased cardiovascular morbidity and mortality. Inflammation plays a crucial role in the pathogenesis of both accelerated atherosclerosis and CMD in ARDs, especially in patients affected by SLE and RA. In this regard, some studies have highlighted the efficacy of immunosuppressants and/or biologics in restoring CMD in these patients. By contrast, the role of inflammation in the pathogenesis of CMD-SSc appears to be much less relevant compared to endothelial dysfunction and microvascular ischemia, with calcium-channel blockers providing some benefits. Few studies have endeavored to assess the occurrence of CMD in IIMs and systemic vasculitis, thus warranting further investigations. The present review summarizes the current evidence on the occurrence of CMD in ARDs, focusing on the role of inflammation and possible therapeutic approaches.

IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE

2019 ◽  
Vol 57 (4) ◽  
pp. 452-461 ◽  
Author(s):  
E. L. Nasonov ◽  
A. S. Avdeeva
Keyword(s):  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Type I Interferon ◽  
Organ Damage ◽  
Immunological Tolerance ◽  
Type I Interferons ◽  
Type I ◽  
Pathological Conditions ◽  
New Evidence

Immunoinflammatory rheumatic diseases (IIRDs) are a large group of pathological conditions with impaired immunological tolerance to autogenous tissues, leading to inflammation and irreversible organ damage. The review discusses current ideas on the role of type I interferons in the immunopathogenesis of IIRDs, primarily systemic lupus erythematosus, and new possibilities for personalized therapy.

Sign in / Sign up

Export Citation Format

Share Document